Equities

Aarti Pharmalabs Ltd

AARTIPHARM:NSI

Aarti Pharmalabs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)606.50
  • Today's Change-3.45 / -0.57%
  • Shares traded58.93k
  • 1 Year change+43.38%
  • Beta--
Data delayed at least 15 minutes, as of Oct 11 2024 11:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), xanthine derivatives, and allied products, situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, and others. Its Caffeine products include caffeine anhydrous, and caffeine anhydrous (granules).

  • Revenue in INR (TTM)19.50bn
  • Net income in INR2.25bn
  • Incorporated2019
  • Employees1.63k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Indoco Remedies Ltd18.22bn766.90m31.38bn5.93k41.28--18.021.728.258.25178.33--------3,072,462.00--6.88--9.8568.6165.594.106.93--2.95--14.028.9113.41-30.78--34.5437.97
Solara Active Pharma Sciences Ltd13.00bn-5.61bn31.83bn2.16k------2.45-143.75-143.75334.17--------6,030,149.00---2.44---3.8437.3441.16-43.17-4.49---1.57-----10.73-1.45-2,458.12---4.81--
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn39.15bn1.23k--123.84----------12.72------------------------0.8228--0.2681--43.84--77.37------
Gufic BioSciences Ltd8.14bn863.69m39.36bn1.45k45.13--38.044.838.708.7081.95--------5,624,707.00--11.46--19.2152.3945.7910.6010.46--8.09--1.3116.8018.128.0731.4653.8314.87
Innova Captab Ltd11.42bn1.06bn41.36bn--30.51--33.293.6223.6923.69236.62------------10.82--18.3833.3825.189.308.04--8.89----16.7224.9038.8436.55104.14--
Hikal Ltd18.03bn677.82m41.87bn2.06k61.80--22.102.325.495.49145.97--------8,749,879.00--5.07--7.5153.0646.783.765.86--2.45--12.19-11.792.34-11.20-7.559.720.00
RPG Life Sciences Limited6.00bn923.20m45.74bn1.27k49.54--41.417.6355.8255.82362.60--------4,721,969.00--16.07--21.7768.4262.9915.3911.99--220.43--29.2713.5012.0129.6051.9828.6046.14
Aarti Drugs Ltd24.23bn1.57bn46.55bn1.06k29.86--22.261.9217.0817.08263.82--------22,770,740.00--9.73--15.7834.3222.236.488.25--7.28-----6.9010.133.0713.8224.96--
Unichem Laboratories Ltd17.28bn-605.50m47.11bn3.19k----90.172.73-8.59-8.59245.15--------5,410,587.00---1.67---2.0362.0056.18-3.50-3.99--0.1401----26.947.6465.15---35.00--
Supriya Lifescience Ltd5.99bn1.35bn47.18bn448.0034.90--31.097.8816.8016.8074.42--------13,370,000.00--19.08--24.0462.7557.1222.5824.71--92.47--2.8823.7415.4732.5624.7583.79--
SeQuent Scientific Ltd14.27bn54.87m48.19bn1.20k905.27--62.043.380.21370.213757.18--------11,939,190.00--1.09--1.7645.3841.970.99021.18--0.9009--35.06-3.605.6870.40--6.96--
Morepen Laboratories Ltd17.45bn1.18bn48.74bn1.62k38.49--32.572.792.312.3134.26--------10,749,300.00--7.90--13.3437.8633.346.775.49--33.34--0.0019.2517.08148.6327.2247.03--
Aarti Pharmalabs Ltd19.50bn2.25bn55.29bn1.63k24.54--18.342.8424.8624.86215.17--------11,983,730.00--------44.20--11.55----18.55-----4.76--12.10------
Sun Pharma Advanced Research Co Ltd684.05m-3.89bn66.90bn409.00------97.79-11.97-11.972.11--------1,672,501.00---61.70---119.3159.8174.49-568.24-163.40---208.33-----68.36-16.21-73.96--15.40--
Orchid Pharma Ltd8.81bn1.12bn70.31bn872.0060.57--47.987.9822.8922.89180.65--------10,101,540.00---0.9734---1.4040.6740.7412.78-2.40--6.08----23.056.4373.595.8457.79--
Data as of Oct 11 2024. Currency figures normalised to Aarti Pharmalabs Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

7.63%Per cent of shares held by top holders
HolderShares% Held
quant Money Managers Ltd.as of 31 Jul 20242.71m2.99%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Jul 2024954.62k1.05%
Morgan Stanley Investment Management Co.as of 30 Jun 2024925.18k1.02%
BlackRock Fund Advisorsas of 04 Jul 2024732.52k0.81%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jul 2024496.33k0.55%
Dimensional Fund Advisors LPas of 04 Jul 2024434.22k0.48%
Norges Bank Investment Managementas of 31 Dec 2023341.42k0.38%
BlackRock Advisors (UK) Ltd.as of 04 Jul 2024130.42k0.14%
Mellon Investments Corp.as of 03 Jul 202497.96k0.11%
Motilal Oswal Asset Management Co. Ltd.as of 31 Jul 202489.57k0.10%
More ▼
Data from 31 Dec 2023 - 31 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.